Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Assets Average (2022 - 2025)

Amylyx Pharmaceuticals has reported Assets Average over the past 4 years, most recently at $347.7 million for Q4 2025.

  • Quarterly results put Assets Average at $347.7 million for Q4 2025, up 56.5% from a year ago — trailing twelve months through Dec 2025 was $347.7 million (up 56.5% YoY), and the annual figure for FY2025 was $263.1 million, down 25.99%.
  • Assets Average for Q4 2025 was $347.7 million at Amylyx Pharmaceuticals, up from $278.7 million in the prior quarter.
  • Over the last five years, Assets Average for AMLX hit a ceiling of $492.0 million in Q4 2023 and a floor of $190.0 million in Q1 2022.
  • Median Assets Average over the past 4 years was $288.9 million (2022), compared with a mean of $319.3 million.
  • Biggest five-year swings in Assets Average: soared 126.26% in 2023 and later plummeted 55.79% in 2025.
  • Amylyx Pharmaceuticals' Assets Average stood at $286.4 million in 2022, then soared by 71.77% to $492.0 million in 2023, then crashed by 54.84% to $222.2 million in 2024, then surged by 56.5% to $347.7 million in 2025.
  • The last three reported values for Assets Average were $347.7 million (Q4 2025), $278.7 million (Q3 2025), and $207.1 million (Q2 2025) per Business Quant data.